<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Activation of group II metabotropic <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> receptor (mGluR) inhibits the excessive release of <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> that may be crucial in the pathogenesis of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This study investigated the protective effects of the group II mGluR <z:chebi fb="4" ids="48705">agonist</z:chebi> (2S,2'R,3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV), against <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> by examining extracellular <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> concentration ([Glu]e) and neuronal damage in a rat model of transient forebrain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0002637'>Cerebral ischemia</z:hpo> was induced by 5 min of bilateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> and <z:hpo ids='HP_0002615'>hypotension</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>DCG-IV (10, 100, or 250 pmol) was administered into the lateral ventricle four times every 12 h from 36 h before the start of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, or administered intraperitoneally (40 micromol/kg) 24 h before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, and the effect of the group II mGluR <z:chebi fb="68" ids="48706">antagonist</z:chebi> (LY341495) was also examined </plain></SENT>
<SENT sid="4" pm="."><plain>[Glu]e in the CA1 subfield was measured by microdialysis during the peri-ischemic period, and the survival rate of CA1 neurons was evaluated 5 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>[Glu]e increased significantly after <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> and reached the maximum at 1 min after reperfusion, then gradually decreased and returned to the preischemic level in the vehicle group </plain></SENT>
<SENT sid="6" pm="."><plain>The intraventricular injection of DCG-IV (250 pmol) significantly attenuated the [Glu]e increase and significantly increased the survival rate of CA1 neurons </plain></SENT>
<SENT sid="7" pm="."><plain>Co-injection of LY341495 reversed the protective effects of DCG-IV </plain></SENT>
<SENT sid="8" pm="."><plain>These results suggest that pretreatment with DCG-IV has neuroprotective effects against ischemic neuronal injuries through the inhibition of the <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> release via the activation of group II mGluR </plain></SENT>
</text></document>